No Detail Found!

The combination of zinc and glibenclamide limits cardiovascular complications in diabetic rats via multiple mechanisms.

Author(s)
Hala Attia Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia; Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt
Nouf Al-Rasheed Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
Nawal Al-Rasheed Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
Laila Faddah Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh, Kingdom of Saudi Arabia
Abstract
Cardiovascular complications have become a major cause of mortality for diabetic patients. Glibenclamide is an effective hypoglycemic agent, but failed to alleviate diabetic complications. This study aimed to evaluate whether the addition of zinc to glibenclamide could mitigate such complications. Diabetes was induced using streptozotocin (60 mg/kg, i.p.). Cardiovascular complications were detected by the significant rise of cardiac enzymes, serum lipids, myocardial oxidative stress and cardiac levels of tumor necrosis factor-α (TNF-α, a marker for inflammation) as well as massive histological changes in the heart wall in diabetic control compared to non-diabetic group. Levels of serum nitric oxide and cardiac vascular endothelial growth factor (VEGF, an angiogenic marker) were lower in diabetic rats. Addition of zinc sulfate (30mg/kg) to glibenclamide (600µg/kg) resulted in significant improvement in cardiac 0.001), in addition to
Publication Details
Page(s) 499-508
DOI DOI not available
Published Journal: Pakistan Journal of Pharmaceutical Sciences, Volume: 28, Issue: 2, Year: 2015

Request the full text from PASTIC

0

Citations

0

Downloads

160

Views